Ensysce Biosciences, Inc.
ENSC Healthcare Biotechnology
Ensysce Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.1 million, down 2.75% from fiscal 2024. In the quarter to June 2026, revenue fell 15.1%, EPS grew 74.7% and free cash flow grew 27.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ENSC
Ensysce Biosciences, Inc. (ENSC) Altman Z-score
Ensysce Biosciences, Inc.'s Altman Z-score for fiscal 2025 is −29.36, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −29.36 | 3.87 |
| FY2024 | −33.23 | 41.88 |
| FY2023 | −75.11 | (34.82) |
| FY2022 | −40.29 | (31.45) |
| FY2021 | −8.85 | 223.67 |
| FY2020 | −232.52 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.36 | — | 0.43 | |
| Retained earnings / total assets | (18.75) | — | −26.25 | |
| EBIT / total assets | (1.37) | — | −4.53 | |
| Market value of equity / total liabilities | 0.52 | — | 0.31 | |
| Sales / total assets | 0.68 | — | 0.68 | |
| Altman Z-score | Distress zone | −29.36 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −67.34 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ENSC Ensysce Biosciences, Inc. | −29.4× |
| PLUR Pluri Inc. compare | −30.4× |
| PTN Palatin Technologies, Inc. compare | −67.7× |
| ASBP Aspire-Lakewood Holdings, Inc. compare | −83.5× |
| ACTU Actuate Therapeutics, Inc. compare | — |
| AEON AEON Biopharma, Inc. compare | — |
| CLRB Cellectar Biosciences, Inc. compare | — |
| INAB IN8bio, Inc. compare | — |
| PASG Passage Bio, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets